MEDIA

EVENTS

Our COVID-19 page is now updated! It now offers you an insight about the approval status of the COVID-19 treatments at the European level. In this framework, the European Medicines Agency (EMA) is committed in expediting the development and approval of safe and effective medicines and vaccines against Coronavirus.

Among the candidate treatments, EMA endorses the use of Dexamethasone in COVID-19 patients on oxygen or mechanical ventilation.

In particular, EMA’s Human Medicines Committee (CHMP) has completed its review of the results from the RECOVERY study, a phase II-III trial including an arm that involved the use of the Dexamethasone in the treatment of patients with COVID-19 admitted to hospital.

Based on the review of the available data, EMA is endorsing the use of Dexamethasone in adults and adolescents from 12 years of age and weighing at least 40 kg.

The use of Dexamethasone resulted in lower 28-day mortality among patients who were receiving either invasive mechanical ventilation or oxygen alone but not among those receiving no respiratory support.

Dexamethasone was first considered a potential treatment for COVID-19 because of its ability to reduce inflammation, which plays a crucial role in the disease process.

The proposed changes to the Dexamethasone product information for patients and healthcare professionals are available here.

To learn more about the current scenario in terms of authorised treatments for COVID-19 and clinical studies performed worldwide, do not hesitate to visit our page and to share it among your colleagues!

Pin It on Pinterest

Share This